Amneal launches focinvez™, the first ready-to-use version of fosaprepitant

Bridgewater, n.j.--(business wire)--amneal pharmaceuticals, inc. (nasdaq: amrx) (“amneal” or the “company”) today announced the launch of focinvez™, a ready-to-use injectable. unlike other versions of fosaprepitant, this single-dose vial product is free of polysorbate 80 and does not require reconstitution or dilution and can be administered directly from the vial using the included vial hanger. focinvez for injection is indicated in adults and pediatric patients 6 months of age and older, in c.
AMRX Ratings Summary
AMRX Quant Ranking